Shared on 29 Oct 25
Fair value Increased 2.41%Analysts have modestly raised their price target for Macquarie Group from A$218.54 to A$223.80. They cite expectations of a gradual earnings recovery, slightly improved revenue growth, and higher profit margins, despite ongoing industry headwinds.
Shared on 15 Oct 25
Fair value Decreased 1.22%Macquarie Group's analyst price target has been revised downward from A$221.24 to A$218.54. Analysts point to a broader earnings recovery lag and persistent macroeconomic pressures in their updated outlook.
Shared on 27 Aug 25
Fair value Increased 1.30%With both the Future P/E and Net Profit Margin for Macquarie Group largely unchanged, the consensus analyst price target has seen only a marginal increase to A$221.24. What's in the News Macquarie Group is set to acquire a 40% minority stake in Portuguese hospital operator Luz Saúde, outbidding CVC Capital Partners and KKR, with the deal valuing Luz Saúde at over €1 billion.
Shared on 23 Apr 25
Fair value Decreased 4.08%AnalystConsensusTarget has decreased revenue growth from 5.9% to 5.3%.
Shared on 17 Apr 25
Fair value Decreased 2.58%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 0.37%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Decreased 1.08%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 1.84%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Increased 1.12%AnalystConsensusTarget has increased revenue growth from 5.1% to 6.0% and decreased shares outstanding growth rate from 0.0% to -0.0%.